GAMMAGARD LIQUID is a ready-to-use liquid medicine that is given in a vein (intravenously) or under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.
What to know about GAMMAGARD LIQUID
There was a clinical study with IV infusions that 61 patients participated in. Of those PI (primary immunodeficiency) patients, GAMMAGARD LIQUID was shown to be effective at a dose of 300 to 600 mg/kg every 3 to 4 weeks for 12 months.
*A patient-year is a patient experience in a clinical trial over the course of 1 year.
†Validated acute serious bacterial infections (ASBIs).
‡The validated other bacterial infections were urinary tract infection (1), gastroenteritis (sometimes called “stomach flu”) (1), and ear infection (2).
381 of the 400 non-serious side effects reported in patients treated with GAMMAGARD LIQUID IV were considered mild (217) to moderate (164). The remaining 5% (19) were severe.
Headaches were the most common side effect (94 of 1,812 infusions).
Side effects may occur with an IV treatment, and they are more likely to occur when you are being treated for the first time or receiving a new medicine. In the clinical trial, the most common side effects with IV infusions of GAMMAGARD LIQUID seen in ≥5% of the patients were headache, fatigue, fever, nausea, chill/shaking chills, pain in the hands or feet, diarrhea, migraine, dizziness, vomiting, cough, hives, asthma, sore throat, rash, joint pain, muscle pain, swelling in the arms or legs, itching, and heart murmur.